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Kansas City, Missouri; North Billerica, Massachusetts; and Charlotte, North CarolinaOBJECTIVES The objective of this observational study was to compare 48-h all-cause mortality
(as well as hospital stay mortality) among critically ill patients who underwent echocardiography either
with or without an ultrasound contrast agent (UCA).
BACKGROUND The safety of perﬂutren-based UCAs has been questioned by the U.S. Food and
Drug Administration (particularly when administered to critically ill patients) following rare reports of
deaths or life-threatening adverse reactions that occurred in close temporal relationship to UCA
administration.
METHODS This was a retrospective observational outcome study conducted in critically ill patients
to compare all-cause 48-h and hospital stay mortality subsequent to echocardiography procedures
performed either with or without a UCA. The study utilized discharge data from a database maintained
by Premier, Inc. (Charlotte, North Carolina). Premier’s database is the largest U.S. hospital–based,
service-level comparative database for quality and outcomes research, and provides detailed resource
utilization data along with patients’ primary and secondary diagnoses and procedure billing codes.
A propensity score–matching algorithm between UCA-enhanced echocardiography patients and
non–contrast-enhanced echocardiography patients was utilized to reduce the potential for imbalance
in covariates of selected patients in the comparison of mortality between groups.
RESULTS Patients undergoing echocardiography with a UCA had lower mortality at 48 h compared
with patients undergoing non–contrast-enhanced echocardiography (1.70% vs. 2.50%), with an odds
ratio ¼ 0.66 (95% conﬁdence interval [CI]: 0.54 to 0.80). Patients undergoing echocardiography with a
UCA had lower hospital stay mortality compared with patients undergoing noncontrast echocardiogra-
phy (14.85% vs. 15.66%), with an odds ratio ¼ 0.89 (95% CI: 0.84 to 0.96).
CONCLUSIONS In critically ill, propensity-matched hospitalized patients undergoing echocardiog-
raphy, use of a UCA is associated with a 28% lower mortality at 48 h in comparison with patients under-
going non–contrast-enhanced echocardiography. These results are reassuring, given previous reports
suggesting an association between UCAs and increased mortality in critically ill patients. (J Am Coll
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41ransthoracic echocardiography (TTE) is an
inexpensive, portable, safe, and reliable im-
aging tool used to evaluate cardiac structure
and function. In critically ill patients, echo-
cardiographic imaging is an essential component of
care and provides data that alter immediate patient
management. In the intensive care unit (ICU),
echocardiograms are limited in quality in over 30%
of studies because of obesity, severe pulmonary
disease, and mechanical ventilation (1). However,Table 1. Demographics and Other Baseline Characteristics
Collected for Each Patient
Patient characteristics (age, sex, race)
Hospital characteristics (Northeast, Midwest, South, and West)
Population served (urban and rural)
Teaching status (teaching, nonteaching)
Hospital size (006–099, 100–199, 200–299, 300–499, 500þ)
Hospital length of stay
Admission type (emergency, elective, trauma, or urgent)
Discharge status (discharged, expired)
48-h all-cause mortality deﬁned as a discharge code of deceased
within 48 h of echocardiography
Major comorbid conditions
Myocardial infarction (410 series)
Congestive heart failure (428 series)
Acute coronary syndromes (411 series)
Ventricular arrhythmias (426.82, 427.1, 427.4, or 427.5 series)
Pulmonary hypertension (415 series, 416.0 series, 416.8 series,
or 416.9 series)
Hypertension (401 series)
Intra-aortic balloon pump (97.44)
Cardiogenic shock (785.51)
Renal failure (584 series, 585 series, or 586 series)
Venous catheterization for renal dialysis (38.95)
Hemodiaﬁltration, hemoﬁltration (extracorporeal) (39.95)
Peritoneal dialysis (54.98)
Diabetes (250 series)
Chronic obstructive lung disease (490.00 and 496.99)
Pneumonia (480.00 and 486.00)
Mechanical ventilation (96.7 series)
Continuous positive airway pressure (93.90)
Stroke (430.00 and 435.99) cerebrovascular disease includes TIA
Sepsis (995.91)
Septic shock (785.52)
Anaphylactic shock (995.0)
Gastrointestinal hemorrhage (578 series)
Transfusion procedure (99.00 and 99.05)
TIA ¼ transient ischemic attack.most nondiagnostic echocardiography studies can
be salvaged with ultrasound contrast agents (UCA)
(1,2). As a result, judicious UCA use is now rec-
ommended by the American Society of Echocar-
diography and the combined specialty Appropriate
Use Criteria for Echocardiography (3,4). The
objective of this observational study was to compare
48-h all-cause mortality (as well as hospital stay
mortality) among critically ill patients who under-
went echocardiography either with or without a
UCA.
METHODS
This was a retrospective observational outcome study
conducted in critically ill patients to compare all-
cause 48-h and hospital stay mortality subsequent
to echocardiography procedures performed either
with or without a UCA. The study used a propensityA B B R E V I A T I O N S
A N D A C R O N YM S
APR-DRG = All Patient Reﬁned
Diagnosis Related Group
CI = conﬁdence interval
cTTE = contrast-enhanced
transthoracic echocardiography
FDA = Food and Drug
Administration
ICU = intensive care unit
nTTE = non–contrast-enhanced
transthoracic echocardiography
TTE = transthoracic
echocardiography
UCA = ultrasound contrast agentscore–matching algorithm between UCA-
enhanced echocardiography patients and
nonenhanced echocardiography patients to
reduce the potential for imbalance in
covariates of selected patients in the com-
parison of mortality between groups. The
study tested the primary hypothesis that
there is no difference in 48-h all-cause
mortality between the non–contrast-
enhanced and UCA-enhanced groups us-
ing an odds ratio obtained from a mortality
analysis of the propensity-matched study
population.
The study utilized discharge data from a
database maintained by Premier, Inc.
(Charlotte, North Carolina). Premier’s
database is the largest U.S. hospital-based, service-
level comparative database for quality and outcomes
research, and provides detailed resource utilization
data along with patients’ primary and secondary
diagnoses and procedure billing codes. Patient di-
agnoses and procedures in the Premier database are
coded using the International Classiﬁcation of
Diseases-9th Revision-Clinical Modiﬁcation (ICD-
9-CM) classiﬁcation system. The Premier database
contains over 2.5 billion daily service records of
patients from 750 geographically diverse hospitals,
and about 45 million records are added each month.
This is approximately 1 in every 4 discharges (26%)
from U.S. hospitals. The demographics and baseline
patient and hospital characteristics collected from
the Premier database for use in this study are listed
in Table 1.
A previous large retrospective study of 4,300,966
consecutive patients, using the Premier database,
Figure 1. Patient Disposition Flowchart
Details of patient selection for the ultrasound contrast agent group and the
group undergoing unenhanced echocardiography. TTE ¼ transthoracic
echocardiography.
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42demonstrated signiﬁcantly lower acute mortality
(odds ratio: 0.76; 95% conﬁdence interval [CI]: 0.70
to 0.82) in all hospitalized patients undergoing
UCA-enhanced echocardiography compared with
all patients undergoing unenhanced echocardiogra-
phy (5). On the basis of the results of this study, we
assumed an unadjusted odds ratio point estimate of
0.80 for our primary hypothesis. If the proportion
in the discordant cell was 0.148 and the 2-sided
95% CI for the log of the expected odds ratio was
extended 0.10 from the log of the observed odds
ratio, the corresponding conﬁdence limits would be
0.724 and 0.884, respectively. Thus, the estimated
sample size was 5,841 patients per cohort (6).
Pre-match sample. Patients were selected for po-
tential matching if they met the following inclusion
and exclusion criteria:
Inclusion criteria:
 Age $18 years;
 Discharged between January 1, 2002, and June
15, 2008;
 Critically ill (deﬁned as patients billed for an
intensive/critical care unit admission as deﬁned
by room and board billing codes); and
 Received a resting TTE with no contrast or with a
UCA (Deﬁnity, perﬂutren lipid microspheres,
Lantheus Medical Imaging, North Billerica, Mas-
sachusetts) during any ICU or critical care unit stay.Exclusion criteria:
 Received a stress (exercise or pharmacological) or
transesophageal echocardiogram; and
 Received a contrast agent other than perﬂutren
lipid microspheres or an unspeciﬁed UCA.
Forty-eight-hour all-cause mortality was deﬁned
as a discharge code of expired on the same day or in
the 24-h period following echocardiography. Hos-
pital stay mortality was deﬁned as a discharge code
of expired on the same day, or on the day following
echocardiography where the time between echo-
cardiography and the discharge code (measured in
service days) was >2.
Matched sample. Contrast-enhanced TTE (cTTE)
and non–contrast-enhanced TTE (nTTE) patients
were matched using propensity score–matching
techniques. The propensity score for subject i
(i ¼ 1,.N) is the conditional probability of being
assigned to the UCA group Zi ¼ 1 versus the
noncontrast echocardiography group Zi ¼ 0, given a
vector of xi of observed covariates. The propensity
score can be thought of as a balancing score, that is,
as a function b(X) of the observed covariates such
that a conditional distribution of X given b(X) is the
same for the UCA group (Z ¼ 1) and noncontrast
echocardiography group (Z ¼ 0) of subjects.
The propensity score was calculated using logistic
regression and included the following patient and
provider characteristics:
 Age;
 Race;
 Admission type;
 Admission source;
 Sex;
 3M All Patient Reﬁned Diagnosis Related
Groups (APR-DRG) (3M Health Information
Systems, Salt Lake City, Utah) severity of illness
assignment;
 3M APR-DRG risk of mortality assignment;
 Discharge status;
 Attending physician specialty;
 Select comorbidities (deﬁned as congestive heart
failure, ventricular arrhythmias, hypertension,
renal failure, venous catheterization for renal
dialysis, hemodialysis, peritoneal dialysis, dia-
betes mellitus, chronic obstructive lung disorder,
pneumonia, stroke, sepsis, septic shock, anaphy-
lactic shock, gastrointestinal hemorrhage, trans-
fusion procedure, myocardial infarction, acute
coronary syndrome, pulmonary hypertension,
intra-aortic balloon pump, cardiogenic shock,
continuous positive airway pressure use, or me-
chanical ventilation);
Table 2. Patient Demographics: Full Dataset (N [ 1,006,381)
Discharges
Noncontrast Group
(n [ 990,159)
Ultrasound Contrast
Agent Group
(n [ 16,222) p Value*
Age, yrs <0.0001
18–44 89,326 (9.02) 1,267 (7.81)
45–64 308,875 (31.18) 6,287 (38.76)
65–74 228,954 (23.11) 4,172 (25.72)
75–79 134,218 (13.55) 1,991 (12.27)
80þ 229,146 (23.13) 2,505 (15.44)
Mean  SD 66.80  15.51 64.96  13.86 <0.0001
Median 69 66
Sex <0.0001
Male 513,030 (51.81) 10,295 (63.46)
Female 477,129 (48.19) 5,927 (36.54)
Race <0.0001
White 641,629 (64.80) 11,988 (73.90)
Black 141,206 (14.26) 1,813 (11.18)
Hispanic 48,244 (4.87) 253 (1.56)
Other/unknown 159,080 (16.07) 2,168 (13.36)
APR-DRG severity of illness <0.0001
Minor 82,580 (8.34) 868 (5.35)
Moderate 210,549 (21.26) 2,541 (15.66)
Major 299,786 (30.28) 4,670 (28.79)
Extreme 396,356 (40.03) 8,118 (50.04)
Unknown 888 (0.09) 25 (0.15)
APR-DRG risk of mortality <0.0001
Minor 147,068 (14.85) 1,685 (10.39)
Moderate 240,808 (24.32) 3,198 (19.71)
Major 281,938 (28.47) 4,708 (29.02)
Extreme 319,457 (32.26) 6,606 (40.72)
Unknown 888 (0.09) 25 (0.15)
Values are n (%) or mean  SD, except as noted. *p values for categorical variables are by the chi-square
test, and for continuous variables, the Student t test was used.
APR-DRG ¼ All Patient Reﬁned Diagnosis Related Group.
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43 Hospital size (deﬁned as the number of licensed,
acute care beds);
 Hospital teaching status;
 Hospital geographic region (deﬁned as North-
east, South, Midwest, or West); and
 Hospital population served (urban or rural).
These clinical and demographic covariates were
selected because of their potential association with
the outcome, or potential confounding effects as
identiﬁed in the research reports (7).
For matching, the goal was to balance power
(sample size) and precision (matching digit), with
the equal distribution of patient and provider
covariates (bias reduction) (8). Thus, patient and
provider covariates were compared at the 3rd, 5th,
and 7th propensity-matching digits to determine
the optimal cutoff. Because the distribution of
covariates remained relatively similar, and the ab-
solute difference in propensity scores diverged at
the second propensity digit, a 3-digit match was
selected. The ﬁnal analytical dataset contained
16,217 cTTE and 16,217 nTTE patients. Figure 1
illustrates the ﬂow of the matching sequence.
Statistical analysis. All database management and
statistical analyses were performed in SAS version
9.2 (SAS Institute, Inc., Cary, North Carolina).
Standard descriptive summaries included the mean,
standard deviation, median, and range for contin-
uous variables, and the frequency and percent of
sample for categorical variables. All statistical tests
of comparisons were 2-sided based on a 5% level of
signiﬁcance. Student t tests were used for compar-
isons of continuous variables, and chi-square tests
for comparisons of categorical variables.
To evaluate the primary and secondary outcomes, a
multivariate logistic regression model was used, and
the model ﬁtness was evaluated using likelihood-
ratio, Hosmer-Lemeshow goodness of ﬁt, and
Concordance c statistics. The ﬁnal model contained
these covariates: treatment (cTTE or nTTE), age
(grouped: 18 to 44, 45 to 64, 65 to 74, 75 to 79, or
$80 years), sex, hemodialysis procedure, sepsis,
transfusion procedure, continuous positive airway
pressure use, and urban versus rural population served
by the hospital. Although all of these covariates were
used in the creation of the propensity-matched
dataset, the aforementioned covariates remained
signiﬁcantly different between the 2 matched groups
and were included to further control for potential
confounding effects because of the imbalance be-
tween the cTTE and nTTE groups.
A sensitivity analysis was conducted to evaluate the
potential inﬂuence of the matching precision on theprimary outcome. Three-, 5-, and 7-digit–matched
datasets were constructed representing 16,217
(3 digit), 15,775 (5 digit), and 10,343 (7 digit)
patients in each matched group. The multivariate
logistic regression model described in the previous
text was run on each dataset and the ﬁndings
compared using a Friedman test. Several subgroup
analyses were also conducted using the same statis-
tical methodology as that of the primary outcome.
RESULTS
The full dataset of patients that met the selection
criteria for this study consisted of 1,006,381
Table 3. Greedy Match Algorithm Propensity Match Counts
Matched Patients Cumulative Matched Patients
Total patients* 32,444
9-Digit match 10,896 10,896 (33.58)
8-Digit match 1,774 12,670 (39.05)
7-Digit match 8,016 20,686 (63.76)
6-Digit match 7,578 28,264 (87.12)
5-Digit match 3,286 31,550 (97.24)
4-Digit match 810 32,360 (99.74)
3-Digit match 74 32,434 (99.97)
Patients not matched at 3 digits 10 (0.03)y
Values are n or n (%). *From the ultrasound contrast agent group (16,222) and potential number from the
noncontrast echocardiography group (16,222) for matching ¼ 32,444. yThe total patients (32,444) minus
the cumulative matched patients (32,434) ¼ 10 (0.03%).
Table 4. Patient Demographics: Matched Dataset (n [ 32,434)
Discharges
p Value*
Noncontrast Group
(n [ 16,217)
Ultrasound Contrast
Agent Group
(n [ 16,217)
Age, yrs 0.3435
18–44 1,237 (7.63) 1,266 (7.81)
45–64 6,321 (38.98) 6,283 (38.74)
65–74 4,298 (26.50) 4,172 (25.73)
75–79 1,916 (11.81) 1,991 (12.28)
80þ 2,445 (15.08) 2,505 (15.45)
Mean  SD 64.9  14.15 64.97  13.85 0.6407
Median 66 66
Sex 0.4530
Male 10,355 (63.85) 10,290 (63.45)
Female 5,862 (36.15) 5,927 (36.55)
Race 0.2787
White 12,050 (74.30) 11,983 (73.89)
Black 1,830 (11.28) 1,813 (11.18)
Hispanic 215 (1.33) 253 (1.56)
Other 2,122 (13.09) 2,168 (13.37)
APR-DRG severity of illness 0.1227
Minor 871 (5.37) 868 (5.35)
Moderate 2,642 (16.29) 2,541 (15.67)
Major 4,794 (29.56) 4,670 (28.80)
Extreme 7,890 (48.65) 8,113 (50.03)
Unknown 20 (0.12) 25 (0.15)
APR-DRG risk of mortality 0.0897
Minor 1,765 (10.88) 1,685 (10.39)
Moderate 3,347 (20.64) 3,198 (19.72)
Major 4,608 (28.41) 4,708 (29.03)
Extreme 6,477 (39.94) 6,601 (40.70)
Unknown 20 (0.12) 25 (0.15)
Values are n (%), except as noted. *p values for categorical variables are by the chi-square test, and for
continuous variables, the Student t test was used.
APR-DRG ¼ All Patient Reﬁned Diagnosis Related Group.
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44patients. Of those, 990,159 were included in the
nTTE group, and 16,222 were included in the
cTTE group. Patient demographics for the full
dataset are summarized in Table 2, and results of
the propensity score matching are shown in Table 3.
The primary analysis was performed at 3 digits
because this met the criteria recommended by
Austin (9) and captured 99.97% of UCA echocar-
diography patients. Signiﬁcant differences in base-
line demographic variables and extent, and severity
of comorbid conditions that had existed between
cTTE and nTTE patients in the full dataset were
resolved by including these covariates in the multi-
variate model (Tables 4 and 5).
The primary endpoint of 48-h mortality was
also analyzed using 3-, 5-, and 7-digit propensity-
matched datasets for added sensitivity. Although
the sample sizes varied between the 3-, 5-, and
7-digit propensity-matched patient samples, 48-h
mortality and the 95% Wald CIs were roughly
equivalent (Friedman’s chi-square test ¼ 0.72). At
3-digit–matched data, cTTE mortality was lower
than nTTE mortality (2.18% vs. 2.97%), with an
odds ratio of 0.72 (95% CI: 0.63 to 0.83). At
5-digit–matched data, cTTE mortality was lower
than nTTE mortality (2.12% vs. 2.92%), with an
odds ratio ¼ 0.71 (95% CI: 0.62 to 0.82). For
7-digit–matched data, cTTE mortality was lower
than nTTE mortality (1.70% vs. 2.50%), with an
odds ratio of 0.66 (95% CI: 0.54 to 0.80) (Figs. 2
and 3).
When mortality throughout the entire hospital
stay was assessed, the matched dataset at 3 digits
showed that cTTE patients had a mortality rate of
14.85%, and nTTE patients had a mortality rate of
15.66% (Fig. 4). This ﬁnding was largely consistent
across a wide variety of major comorbid conditions
and important demographic subgroups such as age
and sex (Table 6). Of note, there is striking
concordance of the results across subgroups, many
of which show statistically signiﬁcantly lower odds
ratios for mortality after cTTE than after nTTE.
Also, there are no subgroups in which signiﬁcantly
greater odds ratios are seen after cTTE.
D I SCUSS ION
In October 2007, the U.S. Food and Drug
Administration (FDA) mandated signiﬁcant prod-
uct labeling changes for UCAs following reports
of post-contrast adverse reactions, including rare
fatalities, which appeared to be temporally related,
though not clearly causally attributable to UCA
administration (10). The present study was
Table 5. Frequency of Comorbid Conditions (Matched Dataset, n [ 32,434)
Discharges
p Value
Noncontrast Group
(n [ 16,217)
Ultrasound Contrast
Agent Group
(n [ 16,217)
Congestive heart failure 7,520 (46.37) 7,592 (46.82) 0.4229
Ventricular arrhythmias 2,222 (13.70) 2,314 (14.27) 0.1408
Hypertension 7,615 (46.96) 7,392 (45.58) 0.0130
Renal failure 5,874 (36.22) 6,058 (37.36) 0.0341
Venous catheterization for
renal dialysis
782 (4.82) 883 (5.44) 0.0110
Hemodiaﬁltration, hemoﬁltration 1,111 (6.85) 1,278 (7.88) 0.0004
Peritoneal dialysis 30 (0.18) 32 (0.20) 0.7993
Diabetes 6,746 (41.60) 6,707 (41.36) 0.6603
Chronic obstructive lung disease 5,263 (32.45) 5,393 (33.26) 0.1243
Pneumonia 3,486 (21.50) 3,600 (22.20) 0.1255
Stroke 1,424 (8.78) 1,452 (8.95) 0.5844
Sepsis 850 (5.24) 883 (5.44) 0.4152
Septic shock 1,132 (6.98) 1,229 (7.58) 0.0382
Anaphylactic shock 11 (0.07) 13 (0.08) 0.6830
Gastrointestinal hemorrhage 549 (3.39) 667 (4.11) 0.0006
Transfusion procedure 3,080 (18.99) 3,344 (20.62) 0.0002
Myocardial infarction 5,964 (36.78) 6,024 (37.15) 0.4901
Acute coronary syndromes 662 (4.08) 723 (4.46) 0.0939
Pulmonary hypertension 1,552 (9.57) 1,643 (10.13) 0.0900
Intra-aortic balloon pump 216 (1.33) 220 (1.36) 0.8471
Cardiogenic shock 1,065 (6.57) 1,147 (7.07) 0.0709
Mechanical ventilation 5,633 (34.74) 5,879 (36.25) 0.0043
Continuous positive
airway pressure
657 (4.05) 786 (4.85) 0.0005
Values are n (%).
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45requested by the FDA to better deﬁne the risk–
beneﬁt relationship associated with cTTE in criti-
cally ill patients.
Three previously published studies evaluated
acute mortality in hospitalized patients undergo-
ing echocardiography with or without a UCA.
The ﬁrst study was a retrospective study perfor-
med at Saint Luke’s Mid America Heart Institute
in Kansas City. In this report, Kusnetzky et al.
(11) compared acute mortality in all hospitalized
patients undergoing echocardiography with a
UCA (n ¼ 6,196) to those patients who did not
receive a UCA (n ¼ 12,475). Patients who
received a UCA exhibited higher clinical acuity
and more comorbidity than patients undergoing
unenhanced echocardiography. Despite the fact
that more critically ill patients received a UCA,
there was no increase in 24-h mortality in patients
receiving the UCA (mortality rate ¼ 0.42% in the
UCA arm and 0.37% in the cTTE arm, p ¼ 0.60).
Of note, this study did not employ propensity
matching.
In a second retrospective study that utilized the
Premier Hospital database (which included all
hospitalized patients, not just the critically ill), Main
et al. (5) evaluated 1-day mortality in 4,300,966
hospitalized patients who underwent echocardiog-
raphy with a UCA (n ¼ 58,254) or who underwent
unenhanced echocardiography (n ¼ 4,242,712).
Unadjusted mortality was similar for both groups
(UCA mortality at 1 day was 1.06% vs. 1.08% for
unenhanced studies [p ¼ 0.613]). A multivariate
regression analysis adjusting for key baseline cova-
riates revealed that patients who received a UCA
were 24% less likely to die within 1 day as compared
with patients who underwent unenhanced echo-
cardiography (odds ratio ¼ 0.76, 95% CI: 0.70 to
0.82).
A third study, similar in design to ours, but
smaller in size, was also previously published (12).
The results indicated no signiﬁcant difference in
mortality in the cTTE group compared with the
nTTE group (odds ratio ¼ 1.18; 95% CI: 0.82 to
1.71; p ¼ 0.37).
In the current study, we have shown an associa-
tion with lower mortality in critically ill patients
undergoing echocardiography with a UCA, in
comparison with propensity-matched patients un-
dergoing echocardiography without a UCA. A
sensitivity analysis comparing the mortality ﬁndings
also conﬁrmed the association with lower mortality
in all matched patient populations (3 digit, 5 digit,
and 7 digit). The inclusion of a wide range of cli-
nical and demographic characteristics in thepropensity score generation controlled for potential
bias because of differences in patient and provider
characteristics. The etiology of the association
between UCA use and lower mortality is not clear.
Possible explanations include better patient man-
agement decisions resulting from more timely
and accurate diagnosis following contrast-enhanced
echocardiography, the avoidance of downstream
invasive tests, or both. Kurt et al. (1) recently sho-
wed in a single-center prospective study of 632
consecutive UCA-enhanced echocardiograms that
contrast echocardiography was associated with
improved image quality, and reduced both the
number of uninterpretable echocardiography studies
and the number of unevaluable left ventricular seg-
ments. This resulted in signiﬁcant improvements in
the evaluation of left ventricular function, better
detection or exclusion of left ventricular thrombus,
Figure 2. Mortality at 48 h in the UCA and Noncontrast Echocardiography Groups
At 3-, 5-, and 7-decimal-place matching, patients undergoing echocardiography with an ultrasound contrast agent (UCA) had lower 48-h
mortality than patients undergoing unenhanced echocardiography.
Figure 3. Odds Ratio for Mortality at 48 h in Patients Receiving an UCA
Odds ratio for mortality in patients undergoing echocardiography with an
ultrasound contrast agent (UCA) at 3-, 5-, and 7-decimal-place propensity score
matching. CI ¼ conﬁdence interval.
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46and frequent changes in patient management as a
result of better diagnostic information.
The present study builds on these previous re-
ports in that: 1) the design of the current analysis
was prospectively approved by the FDA; 2) the
study included only critically ill, hospitalized pa-
tients; and 3) rigorous propensity score matching
was utilized to reduce baseline differences between
the contrast and noncontrast echocardiography
groups.
Study limitations. The limitations include lack of
information on the exact time or cause of death.
However, biases were minimized by selecting all-
cause mortality as the primary endpoint for out-
comes assessments. The absence of temporal
information on the timing of death was similarly
mitigated using the all-cause mortality endpoint and
evaluating mortality at 48 h and throughout the
hospital stay.
Similarly, the use of propensity score matching
addressed the potential for differences in patient
clinical and demographic factors. Despite the
Figure 4. Hospital Stay Mortality in Patients Undergoing
Echocardiography With or Without an UCA
All-cause mortality during hospital stay was lower in patients un-
dergoing echocardiography with an UCA compared with patients
undergoing unenhanced echocardiography. Abbreviations as in
Figure 3.
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47application of propensity matching of comparator
groups of patients, this nonrandomized observational
study could still be subject to hidden biases related toTable 6. Demographic Data for Critically Ill Patients With 48-h Mor
Died
Noncontrast Group
(n [ 16,217)
Ultrasound
(n
Age, yrs
18–44 45/1,237 (3.64) 2
45–64 167/6,321 (2.64) 10
65–74 129/4,298 (3.00) 8
75–79 53/1,916 (2.77) 6
80þ 88/2,445 (3.60) 7
Mean  SD 65.31  15.09 68
Median (range) 67 (20–97)
Sex
Male 292/10,355 (2.82) 210
Female 190/5,862 (3.24) 14
Values are n/N (%), mean  SD, or median (range). *Wald model logistic regression
CI ¼ conﬁdence interval.patient selection due to unadjusted differences in the
patient populations in the UCA-enhanced and non–
contrast-enhanced echocardiography groups. For
example, administrative databases possess limited
granularity. Patients with widely divergent illness
acuity could be classiﬁed with the same ICD-9 code.
It is likely, but not certain, that these differences are
distributed relatively evenly between the UCA and
noncontrast echocardiography groups. Nevertheless,
the large size of this study, concordance of results
across matches of varying precision, persistence of
mortality reduction throughout hospital stay, and
concordance of results across multiple comorbid
conditions provide substantial evidence that
UCA-enhanced echocardiography is associated with
improved outcomes among ICU patients when
compared with nTTE.CONCLUS IONS
In critically ill, propensity-matched hospitalized
patients undergoing echocardiography, cTTE is
associated with a 28% lower mortality at 48 h
in comparison with patients undergoing nTTE.
These results are reassuring, given previous reports
suggesting an association between cTTE and
increased mortality in critically ill patients.
Reprint requests and correspondence: Dr. Michael L.
Main, Saint Luke’s Mid America Heart Institute, 4330
Wornall Road, Suite 2000, Kansas City, Missouri 64111.
E-mail: mmain@saint-lukes.org.tality Data (Matched Dataset, n [ 32,434)
Odds Ratio*
(95% CI) p Valuey
Contrast Agent Group
[ 16,217)
3/1,266 (1.82) 0.43 (0.25–0.73) 0.0017
9/6,283 (1.73) 0.64 (0.50–0.82) 0.0004
0/4,172 (1.92) 0.61 (0.46–0.82) 0.0008
3/1,991 (3.16) 1.2 (0.79–1.7) 0.44
8/2,505 (3.11) 0.85 (0.62–1.2) 0.31
.03  14.26
70 (18–97)
/10,290 (2.04) 0.70 (0.59–0.84) 0.0001
3/5,927 (2.41) 0.73 (0.58–0.91) 0.0050
adjusted odds ratio. yAdjusted odds ratio (Wald).
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